HROW Stock Analysis: Buy, Sell, or Hold?
HROW - Harrow, Inc. Common Stock
$35.43
0.17 (0.48%)
▲
5d:
-2.53%
30d:
-8.22%
90d:
-29.17%
BUY
HIGH Confidence
Analysis Updated: Apr 1, 2026 12:00 AM ET
Earnings: May 14, 2026
Smart Money Accumulation
HROW is down 5.8% this week, but smart money is accumulating calls. Top strike: $40 2026-04-17 with 374 OI. Call ratio: 63% View Scanner →
Strength: 4.2/10
Get Alerted When HROW Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: HROW trading at deep discount. Market pricing in -4.0% annual earnings decline, creating value opportunity for patient investors.
✅ BUY SIGNAL: HROW trading at deep discount. Market pricing in -4.0% annual earnings decline, creating value opportunity for patient investors.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$77.97
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$48.41
26.8% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 22.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: HROW is currently trading at $35.43, which is considered slightly low relative to its 30-day fair value range of $31.80 to $46.69. From a valuation perspective, the stock is trading at a discount (Forward PE: 19.5) compared to its historical average (22.0). Remarkably, the market is currently pricing in an annual earnings decline of 4.0% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, HROW is showing sideways momentum. Immediate support is located at $33.02, while resistance sits at $36.74.
Market Sentiment: HROW has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $70.62 (+99.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, HROW is showing sideways momentum. Immediate support is located at $33.02, while resistance sits at $36.74.
Market Sentiment: HROW has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $70.62 (+99.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Fair Price Range
$31.80 -
$46.69
Company Quality Score
60/100
(HOLD)
Options IV Signal
43th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
86.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Options fairly priced (IV 43th percentile)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 99.3% below Wall St target ($70.62)
Fair Price Analysis
30-Day Fair Range
$31.80 -
$46.69
Current vs Fair Value
SLIGHTLY LOW
Expected Move (7 Days)
±$4.09
(11.5%)
Support & Resistance Levels
Support Level
$33.03
Resistance Level
$36.75
Current Trend
Sideways
Technical data as of
Apr 1, 2026
Fundamental Context
Forward P/E (Next Year Est.)
19.47
Wall Street Target
$70.63
(+99.3%)
Revenue Growth (YoY)
45.4%
Earnings Growth (YoY)
-64.0%
Profit Margin
-2.0%
Valuation Discount vs History
-4.0% cheaper
PE vs Historical
19.5 vs 22.0
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-4.0%
(market-implied from PE analysis)
1-Year Target
$34.01
(-4%)
2-Year Target
$32.65
(-8%)
3-Year Target
$31.35
(-12%)
3-Yr Target (if PE normalizes)
(PE: 19→22)
$35.42
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.4, Growth: 156.3%)
$137.28
(+288%)
Base:
(SPY PE: 19.5, Growth: 156.3%)
$119.58
(+238%)
Bear:
(PE: 16.5, Growth: 156.3%)
$101.64
(+187%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 19.5 to 22.0
Stabilization Target:
$40.04
(+13.0%)
PE Expansion Potential:
+13.0%
Share & Embed Analysis
Last updated: April 02, 2026 7:49 AM ET
Data refreshes hourly during market hours. Next update: 8:49 AM
Data refreshes hourly during market hours. Next update: 8:49 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is HROW showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$178 | 65 BUY |
|
ZTS
Zoetis Inc |
STRONG BUY
19 analysts |
$151 | 57 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$91 | 58 HOLD |
|
HCM
HUTCHMED DRC |
STRONG BUY
14 analysts |
$21 | 65 BUY |
|
TEVA
Teva Pharma Industries L… |
STRONG BUY
11 analysts |
$38 | 64 BUY |
Advanced HROW Option Strategies
Professional options setups generated by AI based on today's HROW price and gamma walls.
